This inventor holds 1 USPTO granted patent. Top assignee: Mvrix Co., Ltd.. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Innovations of Min-Ju Kim in Botulinum Neurotoxin Production
Introduction
Min-Ju Kim is an accomplished inventor based in Suwon, South Korea. He has made significant contributions to the field of biotechnology, particularly in the safe production of botulinum neurotoxin. His innovative methods have the potential to enhance pharmaceutical applications and improve safety in toxin production.
Latest Patents
Min-Ju Kim holds a patent for a method titled "Method for safely producing botulinum neurotoxin." This invention relates to producing botulinum toxin in various fragments that can be reassembled safely. The method involves cleaving the light and heavy chains of the toxin into two or three pieces, which are then combined to form a full-length toxin. This approach addresses the challenges of toxicity, safety, and economic feasibility in toxin production. Additionally, the method allows for the production of water-soluble botulinum toxin using bacteria, significantly shortening the production time compared to existing methods. The fragments produced can also be conjugated with other proteins and nanoparticles, enhancing the pharmaceutical extensibility of the toxin.
Career Highlights
Min-Ju Kim is associated with Mvrix Co., Ltd., where he continues to innovate in the field of biotechnology. His work has garnered attention for its potential applications in medicine and safety.
Collaborations
Min-Ju Kim collaborates with notable colleagues, including Won-beom Park and Joon-Bum Park. Their combined expertise contributes to the advancement of research and development in their field.
Conclusion
Min-Ju Kim's innovative methods for producing botulinum neurotoxin represent a significant advancement in biotechnology. His contributions not only enhance safety and efficiency in toxin production but also open new avenues for pharmaceutical applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile